Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical significance on overall survival. Learn more on SMMT stock here.
Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors
